Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against the specific clinical prospects ...

Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

Ben Taylor, CFO of Recursion, here with us. Thanks so much for joining us. Sure. Great. And first of all, thanks for having us here, Tommie. This is always a terrific conference and great to be here.